Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source.
Meng W, He C, Hao Y, Wang L, Li L, Zhu G. · 2020
Read Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. by Meng W, He C, Hao Y, Wang L, Li L, Zhu G. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7178886.txt.
Introduction
Meng and co-authors review extracellular vesicles as drug delivery vehicles, with a focus on the cells that produce them. Their article appeared in Drug Delivery. Vesicles are tiny membrane bubbles released by most cell types. They carry proteins and genetic material between cells. Their natural origin gives them traits drug makers value.
Compared with synthetic carriers, vesicles are gentle on the body. They are stable and rarely provoke the immune system. Studies have loaded them with small RNAs, proteins, and gene-editing tools. They have also carried small-molecule drugs and nanoparticles. The source cell shapes what a vesicle can do, the authors stress. Isolation methods differ in yield and purity. The review weighs this promise against the practical hurdles.
Catalog record
| CREATOR | Meng W, He C, Hao Y, Wang L, Li L, Zhu G. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source By Wanrong Meng, Chuanshi He, Yaying Hao, Linlin Wang, Ling Li, Guiquan Zhu Published in: Drug Delivery DOI: 10.1080/10717544.2020.1748758 ABSTRACT Abstract Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are nanosized membrane vesicles derived from most cell types. Carrying diverse biomolecules from their parent cells, EVs are important mediators of intercellular communication and thus play significant roles in physiological and pathological processes. Owing to their natural biogenesis process, EVs are generated with high biocompatibility, enhanced stability, and limited immunogenicity, which provide multiple advantages as drug delivery systems (DDSs) over traditional synthetic delivery vehicles. EVs have been reported to be used for the delivery of siRNAs, miRNAs, protein, small molecule drugs, nanoparticles, and CRISPR/Cas9 in the treatment of various diseases. As a natural drug delivery vectors, EVs can penetrate into the tissues and be bioengineered to enhance the targetability. Although EVs’ characteristics make them ideal for drug delivery, EV-based drug delivery remains challenging, due to lack of standardized isolation and purification methods, limited drug loading efficiency, and insufficient clinical grade production. In this review, we summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS. Keywords: Drug delivery, extracellular vesicles, exosomes, microvesicles INTRODUCTION Extracellular vesicles (EVs), including exosomes, microvesicles (MVs), and apoptotic bodies, are nanosized membrane vesicles derived from most cell types. EVs are enriched in blood, saliva, and other biological fluids (Thery et al., 2002; Barile & Vassalli, 2017), carrying and delivering diverse biomolecules from their parent cells to receptor cells (Thakur et al., 2014; Thery, 2015). A growing body of evidence has shown that EVs are important mediators of intercellular communication and thus play significant roles in physiological and pathological processes, including stem cell maintenance, tissue repair, immune modulation, and tumor growth (Valadi et al., 2007; Thakur et al., 2014; Cheng et al., 2018a; He et al., 2018). As ‘molecule carrier’, EVs may serve as novel tools for various therapeutic and diagnostic purpose (EL Andaloussi et al., 2013; Ohno et al., 2016), such as anti-tumor therapy (Poggio et al., 2019), immune-modulatory (Buzas et al., 2014), and drug delivery (Gudbergsson et al., 2019). As a drug delivery vesicle, EVs have been tested for the delivery of siRNAs (El-Andaloussi et al., 2012), miRNAs (Li et al., 2019c), proteins (Haney et al., 2015), small molecule drugs (Zhuang et al., 2011), nanoparticles (Jung et al., 2018), and CRISPR/Cas9 (Lin et al., 2018) into animal models. Owing to their natural origin, EVs are born with high biocompatibility, enhanced stability, and limited immunogenicity, which provide potential advantages over traditional synthetic delivery vehicles, such as liposomes and nanoparticles. Liposomes are round bubbles consisting of an aqueous core encapsulated by natural or synthetic phospholipids (Fan & Zhang, 2013). With this structure, liposomes are ideal drug carriers since hydrophilic drugs tend to be entrapped in the core, while hydrophobic ones will be entrapped within the lipid bilayers (Gulati et al., 1998). Liposomes have been an important choice for drug since their discovery by Alec Bangham and colleagues in 1961 (Bangham & Horne, 1964). Indeed, liposomes are particularly potent in the treatment of some types of cancer, in which they can achieve passive targeting via the leaky tumor vasculature, according to the enhanced permeability and retention (EPR) effect (Torchilin, 2005). As a result of all the advantages of liposomes as drug delivery systems (DDSs), several liposomal drug products are currently available in the market, such as Doxil®, Ambisome®, DaunoXome®, Marqibo®, Onivyde™, Myocet®, etc. (Antimisiaris et al., 2018), while others are under clinical testing, such as CPX-1, CPX-351, En-doTAG-1 (Lip-opack), LEP-ETU, etc. (Palazzolo et al., 2018). Products like Doxil® where the main pharmacological mechanism is passive targeting have poor selectivity toward cancer cells, which induce severe systemic side effects (Antimisiaris et al., 2018). To obtain active target ability in diseased sites, surface ligand modification of liposomes is mostly used in the literature (Jiang et al., 2019). However, clinical trials of these modified liposomes turned out to be barely effective (Allen & Cullis, 2013). The reasons turned out to be that (1) an anatomical barrier exists within tumor; (2) the targeted ligands are unstable and inactive on the membrane surface; and (3) the ligand is insufficient to trigger the binding of the target (Nogueira et al., 2015; Juliano, 2016). Fortunately, EVs have great potential for natural drug delivery, because they can penetrate through anatomical barriers (Rufino-Ramos et al., 2017; Das et al., 2019), keep stability (Zhang et al., 2018a), and maintain sufficient binding effects (Tian et al., 2018). Although EVs’ merits make them ideal for drug delivery, EV-based drug delivery remains challenging, such as short of standardized isolation methods, low drug loading efficiency, and restricted clinical grade production. More importantly, no consensus has been gained on the cell type that could serve as an ideal source of drug delivery-grade EVs. Since EVs inherit parent cell features, EVs derived from different cell types may vary in delivering and targeting properties. In this review, we summarized the current knowledge on the application of EVs as DDSs from the perspective of different cell origin. BIOCHEMICAL PROPERTIES OF EVS Based on the size and biogenesis process, EVs can be divided into three main subpopulations: (i) exosomes, (ii) microvesicles, and (iii) apoptotic bodies. Here, we focus on the first two classes of EVs, which have potentials in drug delivery. Exosomes and MVs are two different forms of EVs representing generic terms for diverse, nanoscale membrane vesicles released by cells (Tkach & Théry, 2016) (Figure 1). [Figure: Scheme of biogenesis of three types of extracellular vesicles (exosomes, microvesicles, and apoptotic bodies) and component of exosome. Exosomes are cell secreted vesicles of ∼100 nm in size and packed with a variety of cellular components including mRNAs, miRNAs, proteins, enzymes, lipids, carbohydrates, etc. The exosome surface is decorated with various membrane proteins responsible for different pathophysiological functions.] Biogenesis of EVs 2.1. EVs were initially illustrated in 1983 when two independent groups found that multivesicular bodies in reticulocytes released such vesicles into the extracellular environment (Pan & Johnstone, 1983; Harding et al., 1984). Few years later, several other groups reported that exosomes are formed by inward budding of limiting membrane of endosomes (Gruenberg & Maxfield, 1995; Babst et al., 2000). Thus, the cytosolic proteins, such as heat shock cognate 70 (HSC70), annexin II, major histocompatibility complex class II (MHC-II), and CD63 (Thery et al., 1999), are found to express on the membrane of exosomes. In contrast, MVs and apoptotic bodies are generated by the outward budding and fission of the cell membrane (EL Andaloussi et al., 2013). Apoptotic bodies are typical membrane blebs released by cells undergoing apoptosis in a wide range of 50–5000 nm. These vesicles contain membrane-enveloped fragments of apoptotic DNA and cytoplasm. They carry ‘find-me’ and ‘eat-me’ molecular signals to attract phagocytes to apoptotic sites and promote clearance of apoptotic cells (Poon et al., 2014). Microvesicles, 20–1000 nm in diameter, are generated by budding from the plasma membrane (Cocucci et al., 2009). Owing to the biogenesis process, the membrane composition of MVs reflects their parent cell more closely than exosomes. Furthermore, owing to highly regulated biogenesis process,